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Abstract
Background: Avidity determination of antigen-specific immunoglobulin G (IgG) antibodies is an
established serological method to differentiate acute from past infections. In order to compare the
avidity of varicella-zoster virus (VZV) IgG in pairs of serum and cerebrospinal fluid (CSF) samples,
we developed a new technique of avidity testing, the results of which are not influenced by the
concentration of specific IgG.
Methods: The modifications introduced for the new VZV IgG avidity method included the use of
urea hydrogen peroxide as denaturing reagent, the adaptation of the assay parameters in order to
increase the sensitivity for the detection of low-level VZV IgG in CSF, and the use of a new
calculation method for avidity results. The calculation method is based on the observation that the
relationship between the absorbance values of the enzyme immunoassays with and without
denaturing washing step is linear. From this relationship, a virtual absorbance ratio can be
calculated. To evaluate the new method, a panel of serum samples from patients with acute and
past VZV infection was tested as well as pairs of serum and CSF.
Results:  For the serum panel, avidity determination with the modified assay gave results
comparable to standard avidity methods. Based on the coefficient of variation, the new calculation
method was superior to established methods of avidity calculation.
Conclusions: The new avidity method permits a meaningful comparison of VZV IgG avidity in
serum and CSF and should be of general applicability for easy determination of avidity results, which
are not affected by the concentration of specific IgG.
Background
In addition to the determination of immunoglobulin M
(IgM) antibodies, the avidity of immunoglobulin G (IgG)
antibodies is an important parameter for the diagnosis or
exclusion of acute infections. Testing of IgG avidity has
been applied for a large variety of pathogens (reviewed in
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[1,2]). A correct diagnosis is especially important for
infections during pregnancy with rubella virus, cytomega-
lovirus and Toxoplasma gondii. Therefore, avidity testing
has been particularly useful for these pathogens.
Determination of antibody avidity is usually based on the
separation of low and high avidity antibodies by denatur-
ing agents in enzyme immunoassays (EIA) or immunoflu-
orescence assays. Several agents such as guanidine
hydrochloride [3], diethylamine [4], thiocyanate [5] or
urea [6] have been used for this purpose. These protein
denaturants have been either included in the sample dilu-
ent (diluting principle) or in the washing buffer after the
serum incubation step (eluting principle). Calculation of
the avidity result has been performed in numerous ways.
Mostly, avidity is expressed as percent ratio of antibody
titers or EIA absorbance values with and without denatur-
ation. Avidity results based on end-point titration with
and without denaturant are considered to be the gold
standard for avidity determination [7]. This technique has
an excellent sensitivity and specificity and is considered
not to be influenced by the concentration of the specific
IgG. To reduce the considerable expense and labour
required for the titration curves, simplified avidity tests
based on single-point determinations using EIAs have
been described [6,8-11]. In these assays, EIA absorbance
values or antibody titers mathematically derived from sin-
gle dilutions have been used for avidity calculation. The
avidity results based on single-point absorbance values
are to some extent influenced by the concentration of spe-
cific IgG, but this is usually not critical for the distinction
between low and high avidity.
Diagnosis or exclusion of acute infection is the most com-
mon but not the only application of avidity determina-
tion. Determination of antibody avidity in pairs of serum
and cerebrospinal fluid (CSF) samples has been suggested
as a diagnostic means to detect intrathecal antibody syn-
thesis [12] and to differentiate viral encephalitis from
multiple sclerosis [13]. Longitudinal measurements of
HIV avidity have been proposed to be useful for the
assessment of HIV progression [14]. Because both of these
applications involve comparative measurements of avid-
ity where small differences may be of diagnostic impor-
tance, a technique for accurate avidity determination is
required which is independent of antibody
concentrations.
The aim of our study was to establish an avidity assay that
can be used for comparison of the avidities of varicella-
zoster virus (VZV) IgG in serum and CSF. In order to
achieve this aim, several modifications of a commercial
VZV IgG assay were introduced. These modifications
include the use of a novel denaturing agent and a new
method to calculate the avidity results.
Methods
Serum and CSF samples
The serum and CSF samples used in this study had been
sent to the virological laboratory at the University of
Würzburg for routine VZV testing and were stored in aliq-
uots at -20°C. Two groups of serum samples were ana-
lyzed for the evaluation of the standard and modified VZV
avidity assay. Group 1 consisted of 28 samples from 19
patients with acute or recent VZV infection and included
5 follow-up samples of patient F19, spanning a period of
11 months. The cases of this group fulfilled the following
criteria: the presence of clinical symptoms suggestive of
varicella, information on the disease onset, and a positive
VZV IgM (Enzygnost Anti-VZV/IgM, Dade Behring, Mar-
burg, Germany). Group 2 consisted of 37 samples from
37 subjects with infection in the distant past. In the sub-
jects of this group, VZV IgG antibodies had been detected
in previous samples taken at least 8 months earlier. For
initial evaluation of the VZV avidity assay for CSF sam-
ples, three sample pairs of serum and CSF were tested, two
from patients with VZV encephalitis (V2.1 and V9.2) and
one from a patient with multiple sclerosis (M22).
Standard VZV IgG avidity determination
VZV IgG avidity determination of serum samples was per-
formed in a semi-automated fashion using the Enzygnost
Anti-VZV/IgG test kit (Dade Behring) with some modifi-
cations. Each of the sera diluted 1:231 in sample buffer
was placed in two antigen coated microtiter plate wells.
After 60 min at 37°C, one well was washed according to
the instructions with the supplied washing buffer. The
other well was washed with a solution of urea, or urea
hydrogen peroxide, in the supplied washing buffer (for
details, see Results) and once with the washing buffer
only. The subsequent steps were carried out according to
the instructions in an automated fashion using the
Behring Elisa Processor III (BEP III; Dade Behring). Perox-
idase-conjugated anti-human IgG was added in a 1:50
dilution and the plate was incubated at 37°C for 60 min.
After three further washing steps with the supplied wash-
ing buffer, tetramethylene benzidine dihydrochloride was
added as substrate and kept at room temperature for 30
min. The reaction was stopped with 0.5 N sulfuric acid.
Control samples of acute and past VZV infections were
included in each run. Where appropriate, VZV IgG anti-
bodies were quantified by an one-point-quantification
method (α-method, Dade Behring) according to the
instructions of the manufacturer.
VZV IgG avidity determination of CSF-serum-pairs
To increase the sensitivity of the VZV IgG EIA in order to
detect low-titer VZV IgG antibodies in CSF, the standard
serum assay was modified as follows. The sample incuba-
tion time was increased to 180 min; the anti-human IgG
was used in a 1:30 dilution and its incubation time wasBMC Infectious Diseases 2004, 4:33 http://www.biomedcentral.com/1471-2334/4/33
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increased to 90 min. All incubations for the CSF assay
were performed at room temperature because variation
was found to be lower compared to incubation at 37°C.
For the serum samples tested for evaluation purposes, the
standard dilution of 1:231 was increased by a factor of 6
to yield a final dilution of 1:1386.
Determination of VZV IgG avidity in CSF was always done
in parallel with serum samples from the same time-point.
Both serum and CSF were tested in at least four dilutions
of a two-fold titration series. The starting dilution for each
sample was derived from routine determinations of VZV
IgG titers. For CSF samples, the starting dilution was at
least 1:6.
Calculation of the avidity index
VZV IgG avidity was calculated by various methods. First,
it was calculated as the ratio of EIA absorbance values
obtained with and without the denaturing washing step.
Alternatively, one-point quantification titers (see above)
instead of absorbance values were used for avidity
calculation.
Two additional methods were used for determination of
VZV IgG avidity in CSF and the corresponding serum sam-
ples. One method involved the use of the software "Avid-
ity 1.2", based on curve-fitting analysis of serial dilutions
[15]. Secondly, we developed a new calculation method
based on our observation from dilution series that the
relationship between the absorbance values obtained
without and with denaturing agents is linear. Thus, the
relationship can be described by the equation y = m × x +
c, where m is the slope, c the intercept, x the absorbance
without the denaturant (absref) and y the absorbance with
the denaturant (absdenat). The m- and c-values of the equa-
tion for each sample were calculated with the software
Excel (Microsoft) from two or more experimentally
derived data points. It is essential, that the absorbance val-
ues obtained without denaturant (absref) fall in the linear
range of the enzyme immunoassay. For the VZV IgG assay
with modified assay conditions, the linear range of the
absorbance values without denturant extended from
approximately 0.200 to 2.800. Avidity was determined
from the linear equation for various virtual x-values as the
percent ratio of the absorbance values with and without
denaturing agent, i. e. avidity = (absdenat/absref) = (m × x +
c)/x. The result was referred to as virtual absorbance ratio.
Results
In order to evaluate the usefulness of the Enzygnost VZV
IgG EIA for avidity testing, a panel of serum samples from
patients with acute VZV infection of defined onset (group
1) and from controls with VZV infection in the distant
past (group 2) was tested. In a preliminary experiment
with three samples from each group, two different dena-
turing conditions were employed. The separation of the
two sample groups with one 3 min washing step using 4
M urea hydrogen peroxide was superior to three 5 min
washing steps with 5 M urea (Table 1, Figure 1). Therefore,
urea hydrogen peroxide was used for the following
experiments.
The results of avidity testing with urea hydrogen peroxide
of all serum samples of group 1 and 2 are shown in Figure
2a. When avidity indices were calculated as the percent
ratio of absorbance values, there was a clear distinction of
the avidity values from both groups. Using a cut-off of 37
%, all samples from patients with disease onset of less
than 50 days had avidity values below the cut-off, while
all samples from the control group with VZV infection in
the distant past had avidity values above the cut-off. Thus,
a cut-off of 37 % resulted in a sensitivity and specificity of
100 % for the detection and exclusion of VZV infections
within in the last 50 days.
The standard result format of the Enzygnost VZV IgG assay
are titers that are mathematically derived from single-
point absorbance values (one-point-quantification).
Because it had been shown previously for the Epstein-Barr
virus (EBV) assay that avidity index calculations based on
Table 1: Comparison of the absorbance values with different denaturing washing conditions in the VZV IgG avidity assay.
VZV infection status 3 × 5 min 5 M urea 1 × 3 min 4 M urea H2O2
Abs (ref)1 Abs (denat)2 Avidity Abs (ref) Abs (denat) Avidity
acute 2.221 1.208 54.4% 2.359 0.546 23.2%
acute 1.829 0.676 37.0% 1.666 0.300 18.0%
acute 1.982 0.457 23.1% 1.869 0.251 13.4%
past 1.487 1.387 93.3% 1.448 0.850 58.7%
past 1.190 0.830 69.7% 1.072 0.580 54.1%
past 2.020 1.671 82.7% 1.929 0.984 51.0%
1absorbance value in EIA without denaturing washing step
2absorbance value in EIA with denaturing washing stepBMC Infectious Diseases 2004, 4:33 http://www.biomedcentral.com/1471-2334/4/33
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one-point-quantification titers gave results better than cal-
culations using absorbance values [11], the avidity indices
were recalculated using VZV IgG one-point-quantification
titers instead of absorbance values. There was an excellent
correlation between both methods of avidity index calcu-
lation, but in contrast to the EBV assay, the one-point-
quantification method was not superior to that using
absorbance values (data not shown).
In general, IgG concentrations in CSF are by a factor of
1:200 to 1:1000 lower than in the corresponding serum.
Therefore, the detection sensitivity of the VZV IgG assay
was increased by prolonging incubations times and
increasing the concentration of the anti-human IgG con-
jugate in order to reliably detect VZV IgG in all CSF sam-
ples from patients with positive serum VZV IgG. To study
the effect of these assay modifications on avidity determi-
nation, all serum samples of group 1 and 17 randomly
chosen samples of group 2 were retested with the modi-
fied assay. All the serum samples were tested in dilution
1:1386 instead of 1:231 used in the standard serum assay.
The results are shown in Figure 2b. An avidity cut-off of 23
% resulted in a sensitivity of 95 % and specificity of 95 %
for the detection and exclusion of VZV infections within
the last 50 days, respectively. Although the standard
serum conditions gave better results, there was again a
clear separation between samples from both groups.
Based on these results, the avidity assay with urea hydro-
gen peroxide and modified assay conditions to increase
the sensitivity for VZV IgG detection was considered
appropriate for use in VZV IgG avidity studies with CSF
and is henceforth called the CSF avidity assay.
For meaningful interpretation of avidity values in CSF, it
is necessary to test serum samples obtained in parallel
with the CSF. Because of the large difference of the IgG
concentrations between serum and CSF, comparison of
the avidity results necessitates independence of IgG con-
centration. To study this issue, CSF and serum samples
were tested in twofold dilution series with the CSF avidity
assay. Avidity was calculated as percent ratio of absorb-
ance values from each dilution. The results for representa-
tive CSF and serum samples are shown in Figure 3. The
avidity indices of most of the samples varied considerably
depending on the sample dilution. For some samples, the
range of avidity indices was greater than 20 %. The coeffi-
cient of variation (CV) was mostly higher than 10 %
(examples in Table 2). Thus, this method could not be
used for comparative testing of serum and CSF samples.
Alternatively, avidity indices were calculated with the soft-
ware "Avidity 1.2", which is based on a mathematical
model described previously by Korhonen et al. [15]. The
software calculates avidity values from two sample dilu-
tions, each tested with and without protein denaturant. To
evaluate the influence of the working dilutions on the
avidity indices obtained with this software, the avidity
indices were calculated from different pairs of dilutions of
the same sample. The results for representative examples
are shown in Table 3. The CV ranged from 5.9 % to 19.7
%.
Because the two methods for avidity calculation described
above were significantly influenced by the chosen work-
ing dilutions, we developed a new calculation method of
antibody avidity. It is based on our observation that the
relationship between absorbance values without and with
denaturing agent is nearly linear. This relationship can
therefore be described by the linear equation y = m × x +
c, where m is the slope, c the intercept, x the absorbance
without denaturant and y the absorbance with denatu-
rant. Representative examples from patients with acute
and past VZV infection and of serum and CSF pairs are
shown in Figure 4. After experimental determination of
the sample-specific m- and c-values, this observation
allows calculating the y-value for any virtual absorbance
without denaturation (x-value). Absorbance results from
two dilutions are required in order to calculate the m- and
c-values for a sample. In order to evaluate the influence of
Optimization of the denaturing washing conditions Figure 1
Optimization of the denaturing washing conditions. VZV IgG 
avidity of a panel of serum samples from patients with acute 
(▲ ) and past (■ ) VZV infection was tested with urea hydro-
gen peroxide (H2O2) and urea as denaturing agent.
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Evaluation of different VZV IgG avidity assays with serum samples from patients with acute (▲ ) and past (■ ) VZV infection Figure 2
Evaluation of different VZV IgG avidity assays with serum samples from patients with acute (▲ ) and past (■ ) VZV infection. 
The Enzygnost Anti-VZV/IgG test kit was used with standard conjugate concentration and standard incubation times (A) and 
with modified assay conditions (B; see text).
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the chosen sample dilution on the avidity index derived
from the virtual absorbance ratio, several samples were
tested in series of twofold dilutions with four or more
steps. The m- and c-values were calculated from different
pairs of dilution steps for each sample. As a result of pre-
liminary experiments, the absorbance 2.0 was chosen as
the virtual x-value for the calculation of avidity values
with the new method. (The linear range of the absorb-
ances in the CSF assay format extended up to 2.8.) Table
3 shows that the CV for the avidity indices calculated by
the new method from different pairs of dilution steps was
lower than the CV obtained with the software "Avidity
1.2" from the same dilution series. Based on theoretical
considerations we speculated that the slope of the linear
equation by itself might represent the avidity of a sample,
i.e. the steeper the linear curve, the higher the avidity. This
was in agreement with the data from follow-up samples of
a patient with acute VZV infection over a period of 11
months (Figure 5). However, comparison of the CVs dem-
onstrated that avidity calculations using a fixed x were less
influenced by the chosen dilution than avidity indices
based on the slope (data not shown).
Influence of the concentration of specific IgG on single-point avidity indices Figure 3
Influence of the concentration of specific IgG on single-point avidity indices. Two-fold dilution series of serum and CSF samples 
were tested in the CSF avidity assay and the avidity index was calculated as the percent ratios of absorbance values for each 
dilution. F19: Follow-up samples of a patient with acute VZV infection. V2.1 and V9.2: Pairs of serum (S) and CSF (C) of a 
patient with VZV encephalitis.
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Table 2: Comparison of avidity values from serum and CSF pairs obtained with different calculation methods from different dilutions 
(absorbance ratios) or different pairs of dilutions (new method and "Avidity 1.2"). For each method, mean values, standard deviations 
(SD) and coefficients of variation (CV) are presented.
V2.1 V9.2 M22
Serum CSF Serum CSF Serum CSF
absorbance 
ratios
Mean (%) 50.2 54.0 59.9 66.4 34.7 38.6
SD (%) 5.6 5.4 7.8 8.5 4.1 6.1
CV (%) 11.1 10.0 13.0 12.8 12.0 15.9
Avidity 1.2
Mean (%) 37.6 45.4 50.5 56.5 23.2 31.9
SD (%) 3.7 3.0 3.0 4.6 2.3 3.6
CV (%) 9.9 6.6 5.9 8.1 9.9 11.4
new method
Mean (%) 49.8 58.4 65.2 72.6 36.5 45.1
SD (%) 2.4 4.1 1.4 7.5 2.0 0.9
CV (%) 4.9 7.1 2.1 10.3 5.6 1.9
Table 3: Calculation of avidity indices from dilution series of representative samples with the software "Avidity 1.2" and with the new 
calculation method described in this paper.
(a) Raw data of dilution series
Serum F19.3 Serum P28 Serum V9.2
Relative dilution1 Abs (ref)2 Abs (denat)3 Abs (ref) Abs (denat) Abs (ref) Abs (denat)
1:1 2.765 0.925 2.668 1.600 2.936 1.948
1:2 1.962 0.626 1.833 1.144 1.943 1.268
1:4 1.428 0.356 1.300 0.727 1.269 0.782
1:8 0.831 0.190 0.824 0.441 0.778 0.463
1:16 0.592 0.106 0.480 0.252 0.409 0.192
(b) Avidity indices obtained from different combinations of dilutions with arithmetic mean, standard deviation (SD) and coefficient of variation (CV)
Serum F19.3 Serum P28 Serum V9.2
Dilutions used for 
calculation
Avidity 1.2 (%) new method (%) Avidity 1.2 (%) new method (%) Avidity 1.2 (%) new method (%)
1:1 & 1:2 9.5 32.0 33.4 61.8 46.1 65.4
1:2 & 1:4 15.2 32.3 40.4 63.7 49.2 65.5
1:4 & 1:8 18.0 25.8 41.5 57.4 50.0 62.9
1:8 & 1:16 11.7 30.0 44.6 54.4 56.6 68.0
1:1 & 1:4 11.6 30.0 35.5 58.7 48.2 64.7
1:2 & 1:8 17.3 32.0 41.8 63.0 50.1 65.4
1:4 & 1:16 13.5 26.4 43.5 56.6 50.2 64.2
1:1 & 1:8 14.7 31.7 41.3 59.0 52.8 65.2
1:2 & 1:16 15.0 32.0 42.0 62.7 51.3 65.4
Mean 14.1 30.2 40.4 59.7 50.5 65.2
SD 2.8 2.5 3.7 3.3 3.0 1.4
CV 19.7 8.4 9.0 5.5 5.9 2.1
1Relative dilution: the starting dilutions were 1:1512 (F19.3), 1:144 (P28), 1:399168 (V9.2)
2absorbance value in EIA without denaturing washing step
3absorbance value in EIA with denaturing washing stepBMC Infectious Diseases 2004, 4:33 http://www.biomedcentral.com/1471-2334/4/33
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Linear relationship between absorbance values without and with denaturing washing step Figure 4
Linear relationship between absorbance values without and with denaturing washing step. Absorption-absorption-diagrams of 
dilution series of samples from (A) patients with acute (closed symbols) and past VZV infection (open symbols) and (B) of pairs 
of serum (closed symbols) and CSF samples (open symbols). For two examples, the determination of y-values for the virtual x-
value 2.0 is represented graphically (dotted lines with arrow heads). Avidity is calculated as the ratio of absorbance y divided by 
absorbance x.
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Further dilution series of CSF and corresponding serum
were tested with the CSF avidity assay in order to confirm
that the influence of the IgG concentration on the avidity
indices derived from the virtual absorbance ratio was min-
imal. Table 2 shows that the CVs with this method were
equally low with CSF and serum. Results obtained with
the software "Avidity 1.2" and results based on the
absorbance ratios of single dilutions are presented for
comparison. Although for two samples the CVs with
"Avidity 1.2" were slightly lower than with the new
method (CSF of V2.1 and CSF of V9.2), for the others the
new method gave lower CVs. Avidity values derived from
absorbance ratios resulted in the highest CVs for all
samples.
Discussion
We established a VZV avidity assay that is suitable for
comparative evaluation of antibody avidity in serum and
CSF samples. In order to achieve this aim several modifi-
cations of a serum VZV avidity assay were necessary.
Though there have been a few studies on the use of avidity
assays for VZV IgG antibodies [16-18], no standard
method or commercial assays exist for the determination
of VZV IgG avidity. Therefore, we first established condi-
tions for a VZV IgG avidity assay that can be used for the
differentiation of acute and past VZV infection. The serum
assay was highly sensitive and specific for the diagnosis
and exclusion of primary VZV infections. However,
diagnostic applications of VZV IgG avidity determinations
with serum samples are rare, because the diagnosis of
acute or reactivated VZV infection is usually made clini-
cally or by virus detection methods.
Urea hydrogen peroxide appeared to be superior to urea
in the optimization experiments for the VZV avidity assay
and presents a novel option for a denaturing agent in
avidity measurements. The denaturing effect of one wash-
ing step with a 4 M solution of urea hydrogen peroxide
Absorption-absorption-diagram of follow-up serum samples of patient (F19) with acute VZV infection tested in the CSF VZV  IgG avidity assay Figure 5
Absorption-absorption-diagram of follow-up serum samples of patient (F19) with acute VZV infection tested in the CSF VZV 
IgG avidity assay. F19.1/2/3/5: 15/28/42/336 days after onset of disease, respectively.
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was more pronounced than that of three washing steps
with a 5 M urea solution. Thus, the denaturing potential
of urea hydrogen peroxide appears to be greater than that
of urea. Furthermore, because of better solubility, han-
dling of solutions of urea hydrogen peroxide is easier than
handling solutions of urea in high molarity. Nevertheless,
the optimal denaturing agent may vary between different
antigens necessitating careful evaluation of denaturing
conditions for each avidity assay.
Under normal conditions, virus specific IgG is present in
the CSF in very low concentrations. With an intact blood-
CSF-barrier, the concentration gradient between serum
and CSF is 200:1 to 1000:1. Thus, the usual serological
methods for antibody quantification in serum are not
sensitive enough to routinely detect specific IgG in CSF.
Therefore, we modified the VZV IgG EIA to increase its
sensitivity. This modification made it possible to detect
and quantify VZV IgG in CSF samples from virtually all
patients with measurable VZV IgG in serum. Correspond-
ing serum samples were always run in parallel with CSF in
the same assay. The CSF and serum dilutions were chosen
individually for each sample pair in order to achieve sim-
ilar absorbance values in the modified EIA. This assay
formed the basis for avidity determination of CSF and the
corresponding serum.
For meaningful comparison of avidity values in serum
and CSF, it is necessary to apply a calculation method that
is independent of the concentration of specific IgG in the
samples examined. One-point determination represents
the simplest method for avidity index calculation, but
such methods did not yield satisfactory results in this
respect. The avidity technique based on end-point-titra-
tion is not influenced by the IgG concentration and is
considered the reference method for avidity determina-
tion [1,7]. However, it is relatively laborious and reagent
consuming, requiring two distinct dilution series for the
assays with and without protein denaturant. Therefore, we
attempted to use the logistic approach based on end-
point-titration, with fewer dilutions per sample [15]. This
method works well in distinction between acute and past
infections from samples of serum. However, under the
conditions of the CSF avidity assay we found that the
results of the logistic model were not uniformly
independent of the sample working dilutions, albeit with-
out straightforward dose-dependence of specific IgG. The
reason for this limitation with our assay may lie in its
modifications to increase sensitivity. Possibly, the curve
fitting obtained with the logistic model would have to be
adjusted in order to account for the special conditions of
the CSF avidity assay.
Searching further for a simple calculation method of avid-
ity indices independent of IgG concentration and sample
dilutions, we observed a linear relationship between the
absorbance values of the assays without and with denatur-
ing washing conditions. After performing an avidity assay
of two dilutions of a given sample, this relationship can
be exploited to calculate a linear equation from the two
pairs of absorbance values (with and without denatura-
tion). The only requirement is that all absorbance values
should fall in the linear range of the EIA. Once for a given
sample the linear equation is experimentally determined,
the equation can be used for calculation of the virtual
absorbance value with denaturation (absdenat) for any vir-
tual absorbance value without denaturation (absref). The
avidity index is then calculated as the ratio of the two
virtual absorbance values (absdenat/absref). Thus, if a fixed
absref is chosen for all samples to be compared, the avidity
index becomes independent of the concentration of spe-
cific IgG in the samples. These theoretical considerations
have been confirmed by the results obtained from dilu-
tion series in this study. It will be interesting to test the
general applicability of this method for standard avidity
assays by comparison with single-point and end-point
avidity determinations.
Conclusions
In summary, we have described several modifications of
existing avidity techniques that have the potential to
broaden the use of avidity assays in diagnosis and
research. Urea hydrogen peroxide is a novel denaturing
agent, which appears to be advantageous compared to
urea in terms of handling conditions. The new calculation
method of avidity indices based on a linear equation with
fixed reference absorbance values is cost-effective and sim-
ple and has the potential to substitute other avidity calcu-
lation procedures. The CSF avidity assay in combination
with the new calculation method allows for determina-
tion of the avidity of VZV IgG in corresponding serum and
CSF samples with high precision and independent of the
VZV IgG concentration. These features are necessary in
order to study the avidity maturation in serum and CSF in
patients with intrathecal synthesis of VZV-specific IgG
antibodies.
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